Table 1.
Characteristics of patients in validation sets I and II
| Validation set I (n = 25) | Validation set II (n = 66) | ||
|---|---|---|---|
| Age, years | 71 (68, 77) | 69 (63, 73) | |
| Gleason ≤6 | 1 (4.8 %) | 5 (10 %) | |
| Gleason = 7 | 5 (24 %) | 16 (32 %) | |
| Gleason ≥8 | 15 (71 %) | 29 (58 %) | |
| Bone metastasis | 19 (76 %) | 37 (59 %) | |
| Visceral metastasis | 3 (12 %) | 26 (41 %) | |
| PSA (ng/mL) | 38 (7, 437) | 221 (39, 657) | |
| Hemoglobin (g/dL) | 11.9 (11.2, 13.3) | 11.1 (10.0, 12.4) | |
| LDH (U/L) | 223 (200, 273) | 342 (256, 561) | |
| AP (IU/L) | 84 (69, 194) | 163 (85, 399) | |
| Prior treatment | Docetaxel | 7 (28 %) | 52 (79 %) |
| Abiraterone | 4 (16 %) | 11 (17 %) | |
| Cabazitaxel | 5 (20 %) | 0 | |
| Sipuleucel-T | 3 (12 %) | 0 | |
| Enzalutamide | 2 (8 %) | 0 | |
| Number of different prior treatments | 0 | 13 (52 %) | 14 (21 %) |
| 1 | 4 (16 %) | 41 (62 %) | |
| 2 | 8 (32 %) | 11 (17 %) | |
| Median follow-up, months | 28.9 | 30.8 | |
| Number of events | 15 | 58 | |
Data are median (0.25 quantile, 0.75 quantile) or count (%). Median follow-up time was calculated based on survivors. All samples in validation set II were drawn right before the next treatment. The samples in validation set I were obtained either right before the next treatment or between two treatments. None of these blood samples were collected immediately after a treatment to reduce the acute impact of treatments